5 reports

Given the consistent activity signals seen in both our open-label and placebo-controlled trials, we also intend to examine the development pathways for several of our other proprietary pipeline compounds into the treatment of a variety of psychiatric disorders, such as major depression,

  • Ultrasound
  • FUJIFILM Holdings Corporation
  • GE Healthcare Limited
  • Hitachi, Ltd.
  • Samsung Medison

Given the consistent activity signals seen in both our open-label and placebo-controlled trials, we also intend to examine the development pathways for several of our other proprietary pipeline compounds into the treatment of a variety of psychiatric disorders, such as major depression,

  • Therapy
  • Ultrasound
  • Japan
  • Company
  • Toshiba Corporation

Abilify® is a leading antipsychotic agent used worldwide for the treatment of bipolar I disorder, schizophrenia, major depressive disorder and irritability associated with autistic disorder.

  • Ultrasound
  • North America
  • United States
  • Forecast
  • GE Healthcare Limited

Abilify® is a leading antipsychotic agent used worldwide for the treatment of bipolar I disorder, schizophrenia, major depressive disorder and irritability associated with autistic disorder.

  • Healthcare
  • Ultrasound
  • United States
  • Company Financials
  • GE Healthcare Limited

Abilify® is a leading antipsychotic agent used worldwide for the treatment of bipolar I disorder, schizophrenia, major depressive disorder and irritability associated with autistic disorder.

  • Eyewear
  • Medical Device
  • Ophthalmology
  • Ultrasound
  • Vitreoretinal Surgery Device